Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04093024 · ClinicalTrials.gov registry record · Phase 3
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
A Phase 3 study of Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
- 20
- Study locations
NCT04093024 is a Phase 3 study of Lung Diseases, Interstitial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 39 participants, below the 12,505-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04093024, a Phase 3 study of Lung Diseases, Interstitial, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of the study is to evaluate dose-exposure and safety of nintedanib in children and adolescents with fibrosing Interstitial Lung Disease (ILD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nintedanib
Study Locations (20)
Other
- Hospital de Pediatría " Prof. Dr. Juan P. Garrahan" - CABA
- Hospital de Niños Dr. Ricardo Gutierrez - CABA
- INSARES - Mendoza
- Brussels - UNIV HUDERF - Brussels
- Serviços Medicos Respirar Sul Fluminense - Barra Mansa
- Centro de Pesquisa Clinica do Instituto da Crianca - HCFMUSP - São Paulo
- Teaching Hospital Motol, Oncology Clinic - Prague
- Aarhus University Hospital - Aarhus N
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center - Pittsburgh
California
- Children's Hospital Los Angeles - Los Angeles
Colorado
- Children's Hospital Colorado - Aurora
Indiana
- Riley Hospital for Children at Indiana University Health - Indianapolis
Missouri
- Children's Mercy Hospitals and Clinics - Kansas City
New York
- Weill Cornell Medicine - New York
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-12-03 |
| Est. Completion | 2022-05-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04093024
The ClinicalTrials.gov registry entry for NCT04093024 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,505-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (100% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Diseases, Interstitial appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04093024 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT04093024 about?
NCT04093024 is a clinical study titled "A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)". The main objective of the study is to evaluate dose-exposure and safety of nintedanib in children and adolescents with fibrosing Interstitial Lung Disease (ILD).
What is the current status of trial NCT04093024?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2019-12-03. Estimated completion is 2022-05-24.
What conditions does trial NCT04093024 study?
This clinical trial studies the following conditions: Lung Diseases, Interstitial.
What interventions are being tested in trial NCT04093024?
The interventions under investigation include: Placebo (DRUG), Nintedanib (DRUG).
Who is sponsoring clinical trial NCT04093024?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04093024 being conducted?
This trial has 20 study locations across California, Colorado, Indiana, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases, Interstitial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RECRUITING · Phase 3
-
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
RECRUITING
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
-
Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease
RECRUITING · Phase 1
-
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
RECRUITING · NA
-
Cough Capture as a Portal Into the Lung
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.